Dry eye drug combo safety trial pulled before it started
NCT ID NCT07111013
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to check the long-term safety of a new eye drop that combines two active ingredients (lifitegrast and perfluorohexyloctane) for people with dry eye disease. It was a follow-up for people who had already completed an earlier study. However, the trial was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lifitegrast and perfluorohexyloctane eye drops
What this could lead to
If successful, this could confirm a safe long-term treatment option for dry eye disease.
What could go wrong
The trial was withdrawn before enrolling anyone, so no data was collected. The combination's long-term safety remains unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.